ALPHAGAN® P ophthalmic solution is approved for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
Important Safety Information
ALPHAGAN® P (brimonidine tartrate ophthalmic solution) 0.1% should not be used in patients receiving monoamine oxidase (MAO) inhibitor therapy. Adverse events occurring in approximately 10% to 20% of the subjects included: allergic conjunctivitis, ocular redness, and itching. Adverse events occurring in approximately 5% to 9% included: burning sensation, increased ocular lymph nodules, increased ocular pressure, ocular allergic reaction, dry mouth, and blurred vision.
Please click here for full Prescribing Information.
|
©2008 Allergan, Inc., Irvine, CA 92612 | ® marks owned by Allergan, Inc. |